Emapalumab’s role in a severe and treatment-resistant paediatric macrophage activation syndrome
ARP Rheumatology · 2026
DOI: 10.63032/bpdo4893 ↗Kurz gefasst
Fallbericht in der Zeitschrift ARP Rheumatology, 2026. Verfasst von Roberto Pereira da Costa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa. Hauptthemen laut MEDLINE: Macrophage Activation Syndrome, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa.
- Unidade Local de Saúde Lezíria.
Zitieren
APA
Pereira da Costa, R., Lima, M., Guedes, S., Vieira, M., Costa-Reis, P., Claro, A., Dias Curado, A., Prata, F., Esteves, I., Campanilho Marques, R., Gonçalo Marques, J., & Oliveira-Ramos, F. (2026). Emapalumab’s role in a severe and treatment-resistant paediatric macrophage activation syndrome. ARP Rheumatology. https://doi.org/10.63032/bpdo4893
Vancouver
Pereira da Costa R, Lima M, Guedes S, Vieira M, Costa-Reis P, Claro A, et al. Emapalumab’s role in a severe and treatment-resistant paediatric macrophage activation syndrome. ARP Rheumatology. 2026. doi:10.63032/bpdo4893
BibTeX
@article{PereiradaCosta2026,
author = {Pereira da Costa, Roberto and Lima, Mariana and Guedes, Sofia and Vieira, Marisa and Costa-Reis, Patrícia and Claro, Ana and Dias Curado, Ana and Prata, Filipa and Esteves, Isabel and Campanilho Marques, Raquel and Gonçalo Marques, José and Oliveira-Ramos, Filipa},
title = {Emapalumab’s role in a severe and treatment-resistant paediatric macrophage activation syndrome},
journal = {ARP Rheumatology},
year = {2026},
doi = {10.63032/bpdo4893}
}
EUVIMED